(Note: Not an IPO:  We are offering American Depositary Shares (ADS) based on the closing price of our ordinary shares on the Frankfurt Stock Exchange on Oct. 22, 2021, of €44.99 and assuming an exchange rate of $1.163 per euro. Our shares are listed on the Frankfurt Stock Exchange under the symbol “EVT” and under the ISIN DE0005664809. Our ADSs are currently traded on the over-the-counter market in the United States under the symbol “EVTCY.” Each ADS represents one-half of an ordinary share.)

We are an industry-leading drug discovery and development partner for the pharmaceutical and biotechnology industry. Our mission is to discover best and first-in-class medicines for a broad range of difficult to treat diseases in collaboration with our partners. To that end, we have built a comprehensive suite of fully integrated, next generation technology platforms which we believe will transform the way new drugs are discovered. By leveraging the advanced capabilities of our integrated platforms, we are able to provide solutions to our partners that enable significant improvements in the quality of new drugs while accelerating the drug discovery process and reducing the high cost of attrition often associated with traditional drug discovery processes.

(Note: Evotec SE trimmed its ADS offering at pricing on Nov. 3, 2021, by pricing 20 million American Depositary Shares, down from 22 million in the prospectus, at US$21.75 – down from the assumed offering price of US$26.16, to raise $435.0 million.)